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s0010 Introduction
p0010 Neurotoxicity refers to the direct or indirect effect of chemicals
that disrupt the nervous system of humans or animals.
Numerous chemicals can produce neurotoxic disease in
humans, and many more are used as experimental tools to
disturb or damage the nervous system of animals. Some act
directly on neural cells, others interfere with metabolic
processes on which the nervous system is especially dependent.
Some disrupt neural function; others induce maldevelopment
or damage to the adult nervous system. Perturbations may
appear and disappear rapidly, evolve slowly over days or weeks
and regress over months or years, or cause permanent deﬁcits.
Neurotoxicity is usually self-limiting after exposure ceases and
rarely progressive in the absence of continued exposure,
although there may be a signiﬁcant delay between exposure
and manifestation of neurotoxic effects.
s0015 Occurrence
p0015 Chemicals with the potential to disrupt the mammalian
nervous system may occur naturally (neurotoxins) or arise by
synthesis (neurotoxicants). While chemicals with neurotoxic
potential are conveniently termed ‘neurotoxins’ or ‘neuro-
toxicants,’ this is not an intrinsic property but rather the
description of an effect that may occur if the tissue concentra-
tion exceeds a certain threshold. Biological chemicals with
neurotoxic properties often have high target speciﬁcity and
toxic potency, discrete biological actions, and are among the
best understood mechanistically. Examples of chemicals with
direct or indirect neurotoxic potential are found in bacteria,
algae, fungi, plants, coelenterates, insects, arachnids, molluscs,
amphibians, reptiles, ﬁsh, and certain mammals (Table 1).
p0020 Other less potent naturally occurring substances exhibit
neurotoxic effects when encountered in large concentration for
sufﬁcient periods of time. Examples include metals (arsenic, lead,
mercury) and certain compounds containing these elements
(methylmercury) (Table 2). Some elements (manganese, selenium)
and compounds (vitamin B6) in this group, while neurotoxic in
sustained heavy doses, are required in smaller amounts to
support normal physiological function, including that of the
nervous system. Natural substances (thiaminase) that interfere
with required substances (thiamine) are also associated with
neurological disease in animals and humans.
p0025 Synthetic chemicals with neurotoxic potential (Table 2) are
most commonly encountered in the form of prescription
(ethambutol, isoniazid, vincristine) and over-the-counter phar-
maceutical agents (bismuth preparations), domestic products
used in antidandruff shampoos (pyridinethione), fragrance raw
materials (2,6-dinitro-3-methoxy-4-tert-butyltoluene), pyrolysis
products in broiled, baked, or fried food (acrylamide), beverages
(ethanol), workplace chemicals (n-hexane), pest-control agents
(aldrin), environmental pollutants (mercury), and substances
(methamphetamine) used to induce euphoria. Others are asso-
ciated with special applications, such as chemical warfare in
military and civilian settings (sarin).
p0030Direct-acting substances with neurotoxic potential are sup-
plemented by other agents that initiate neurological change as
a consequence of effects on another organ system on which the
brain depends for normal function. Substances that target the
liver, kidneys, or lungs fall into this category, as do agents that
interfere with the continuous supply of oxygen (cyanide, azide)
and glucose (6-chloro-6-deoxyglucose) required by the nervous
system for normal function. Chronic liver failure and manga-
nese intoxication are both associated with high signal abnor-
malities in the basal ganglia on T1-weighted magnetic
resonance images, suggesting that the metal accumulates
because it cannot be cleared normally by the liver.
s0020Neurotoxic Effects
p0035The nervous system has a vast repertoire of functional reactions
to chemical perturbation, and these responses give rise in the
aggregate to a plethora of neurological and psychiatric
phenomena, many of which recapitulate the clinical manifes-
tations of disease of nontoxic origins. Large single doses of
certain substances, such as organic solvents (ethanol, toluene)
that intoxicate, induce functional changes in the organism that
appear and disappear rapidly. Other agents, such as the anti-
cholinesterase nerve agents, induce a subset of functional changes
(e.g., parasympathomimetic effects) that reverse when the
inhibited target protein (acetylcholinesterase) is reactivated or
replaced. Sometimes, as in the case of methanol, the latent
period (hours) between exposure and effect is associated with
the production and action of a toxic metabolite (formate).
Single exposures to large amounts of other substances (arsenic,
t0010Table 1 Naturally occurring substances with mammalian neurotoxic
potential
Life form Substance with neurotoxic potential
Bacterium Diphtheria toxin
Alga Anatoxin-a
Fungus 3-Nitropropionic acid
Plant L-BOAA
Coelenterate Palytoxin
Insect Apamin
Arachnid Scorpion toxins
Molluscs Conotoxins
Fish Ciguatoxin
Amphibia Batrachotoxin
Reptile Dendrotoxin
Bird Batrachotoxin
Mammal Vitamin A
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mercury, thallium) may be followed by a latent period of days or
weeks before structural and functional changes become
evident. While certain substances (acrylamide) can induce
neurological damage after single large exposures, smaller doses
over a long period of time are also effective, but the pattern of
neurological deﬁcit may be distinct in the two dosing scenarios.
Neurotoxic disorders typically progress during the period of
exposure and immediately following exposure, when the
pathological events already in progress may take time to unfold
before stabilization or recovery can begin. Prospects for func-
tional recovery depend on the presence or absence of tissue
damage, the extent of damage, and whether neuropathological
changes have occurred in the central nervous system (CNS)
(poor prognosis).
p0040 An unanswered question is whether in some instances
disease may progress or recur after chemical exposure has
ceased. Certainly, catastrophic and fatal neurodegeneration
after a delay period may follow acute carbon monoxide
poisoning, but this is an isolated example. Relapses occur in
ciguatoxicity presumably because the offending agent is released
from fat stores under certain physiological conditions.
Progressive visual defects may occur from release of chloroquine,
which has been sequestered in the choroid layer of the eye.
There is also concern that certain substances (carbon disulﬁde,
organochlorine pesticides) might predispose or accelerate the
onset of age-related diseases of the nervous system, such as
Parkinson’s disease. Finally, research is underway to determine
whether certain DNA-damaging agents (methylazoxymethanol
(MAM)) may predispose neurons to tardive degeneration
because of their low capacity for DNA repair. Studies reported
in 2011 suggest that genotoxins such as MAM have biphasic
effects depending on the ability of the targeted cells to divide:
cycling cells undergo proliferation as a result of mutation
arising from DNA damage (O6-methylguanine (O6-mG)),
while noncycling neurons respond through related signal
transduction pathways with degeneration.
s0025Principles of Nervous System Vulnerability
p0045There are many factors that determine the response of the
nervous system to chemical exposure. Species, gender, genotype,
age, nutritional status, body temperature, and activity are key
determinants, as are chemical access, structure, and biotrans-
formation. The time of day has been found to affect the degree of
ataxia induced in mice treated with sodium nitroprusside.
p0050Metabolic activity of the brain may serve to activate
a neurotoxic substance, as in the conversion of methylphenyl-
tetrahydropyridine (MPTP) to the mitochondrial toxin N-methyl-
4-phenylpyridinium ion (MPPþ), which targets substantia nigra
neurons and precipitates parkinsonism in humans and other
mammals. b-N-Methylamino-L-alanine (L-BMAA) is metabolized
t0015 Table 2 Heavy metals and synthetic substances with neurotoxic potential
Substance Primary neurotoxic effects
Acrylamide Peripheral neuropathy (axonal degeneration), cerebellar ataxia
Arsenic Acute encephalopathy (brain swelling and hemorrhage), peripheral neuropathy (axonal degeneration)
Barbiturates Acute encephalopathy (sedation and coma), chronic encephalopathy, developmental neurotoxicity,
facilitated g-aminobutyric acid neurotransmission
Carbamate pesticides Acute encephalopathy (cholinergic syndrome), neuromuscular transmission dysfunction,
acetylcholinesterase inhibition
Carbon disulﬁde Acute psychosis, chronic peripheral neuropathy (axonal degeneration), parkinsonism
Carbon monoxide Encephalopathy/delayed parkinsonism, neuronal and tissue necrosis secondary to hypoxia
Carbon tetrachloride Acute encephalopathy, visual dysfunction
Doxorubicin Progressive ataxia (rodents), sensory neuronal degeneration
Ethanol Fetal alcohol syndrome, acute encephalopathy (agitation, sedation, ataxia, coma), chronic encephalopathy
(cognitive impairment, dementia), myopathy, peripheral neuropathy (vitamin B1 deﬁciency?)
n-Hexane Peripheral neuropathy (axonal degeneration)
Lead, inorganic Peripheral neuropathy (axonal loss and demyelination), acute encephalopathy (seizures), cognitive
dysfunction
Manganese, inorganic Emotional disturbance, psychoses, parkinsonism/dystonia, neuronal degeneration in striatum and globus
pallidus
Mercury, inorganic Cerebellar syndrome (tremor, ataxia), psychobiological reaction (anxiety, personality changes, memory loss)
Methanol Optic neuropathy (axonal degeneration, primary demyelination), extrapyramidal syndrome (necrosis of
putamen), retinopathy (edema)
Methylmercury Developmental toxicity and teratogenesis, visual dysfunction (tunnel vision), cerebellar syndrome (ataxia),
peripheral neuropathy, chronic encephalopathy (cognitive dysfunction)
Organophosphorus compounds
(pesticides and warfare agents)
Cholinergic syndrome (certain compounds), peripheral neuropathy (certain compounds only),
acetylcholinesterase inhibition
Phenytoin Fetal phenytoin syndrome, cerebellar syndrome (ataxia, nystagmus), chronic encephalopathy (cognitive
dysfunction), extrapyramidal syndrome (chorea, dyskinesia), peripheral neuropathy
Toluene Acute encephalopathy (sedation, coma), chronic encephalopathy (cognitive dysfunction)
Tricyclic antidepressants Seizure disorder (myoclonus), psychobiological reaction (serotonin syndrome, anticholinergic syndrome),
tremor, extrapyramidal syndrome (dyskinesia)
Trimethyltin Acute encephalopathy (neuronal degeneration of limbic system) – rodents, chronic encephalopathy
(cognitive dysfunction, neuronal loss in hippocampus)
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to formaldehyde in rodent brain tissue, thereby transforming an
excitant amino acid to a potential genotoxin. Hepatic biotrans-
formation is broadly concernedwith the conversion of lipophilic
chemicals to less toxic hydrophilic metabolites (Phase I) and
their conjugation (Phase II) prior to excretion. Occasionally,
Phase I metabolism may increase the neurotoxic potential of an
exogenous substance, as in the case of the stepwise conversion of
n-hexane to 2,5-hexanedione, a solvent that targets neuroproteins
and causes nerve ﬁber degeneration in the CNS and peripheral
nervous system (PNS). Co-exposure to substances such asmethyl
ethyl ketone or toluene may impact Phase I enzyme function and
thereby markedly modify (increase or decrease, respectively) the
quantitative neurotoxic response to n-hexane.
p0055 Most mammalian species reproduce the qualitative
response of the human nervous system to chemical perturba-
tion, but the sensitivity may differ markedly among species. For
example, relative to humans, primates, and cats, rodents are
relatively refractory to organophosphate-induced neuropathy.
Gender is a factor in risk for tardive dyskinesia (stereotypic
behaviors, dystonia, myoclonus, and tics) associated with the
dopamine receptor-blocking properties of neuroleptic drugs.
Gender as a determinant of biotransformation may be less
important in humans than in rats, where marked differences in
the metabolism and consequent functional responses to indi-
vidual chemicals such as parathion may be noted. 3,4-Methyl-
enedioxymethamphetamine (MDMA) may depress serotonin
more in female than male rats. Differences in genotype may
determine the presence of neurotoxic responses, as in the rare
mitochondrial polymorphism that results in hypersensitivity to
aminoglycoside-induced deafness. Age in humans is generally
associated with increased susceptibility to many chemical
substances largely because of reductions in biotransformation,
renal clearance, and biliary excretion, as well as factors such
as reduced body weight, inanition, and polypharmacy that
promotes drug and chemical interactions. In addition, neurons
display age-related increases of DNA damage, regional nerve
cell loss (e.g., substantia nigra), and axonal pathology (e.g.,
spinal roots). Nutritional status may predispose to human
neurotoxicity as seen in minimally nourished Africans who
develop spastic paraparesis from a combination of sulfur
amino acid deﬁciency and exposure to cyanogenic substances,
both of which arise from dietary dependence on the root
crop cassava (Manihot esculenta). Substances that interfere
with vitamin production or utilization, including thiamine
(pyrithiamine), riboﬂavin (quinacrine), niacin (3-acetylpyridine,
6-aminonicotinamide), or cyanocobalamin (nitrous oxide),
produce various types of severe neurological deﬁcit, as does
excessive exposure to vitamin A. Other types of neuro-
degeneration are seen with substances that chelate physiolog-
ically important metals ions (pyridinethione, 8-hydroxyquinolines,
ethambutol), such as zinc. Excessive dietary intake of sulfur
and selenium produces neuronal lesions in ruminants and
pigs, respectively. Body temperature is an important determi-
nant of the neurotoxic response of rodents, primates, and
possibly humans to the psychostimulant methamphetamine:
hyperthermia exacerbates and hypothermia attenuates
methamphetamine-induced dopamine neurotoxicity. Finally,
excessive physical activity has been associated with the acute
onset of central motor weakness in cassavism and lathyrism,
the latter associated with dietary dependency on grasspea
(Lathyrus sativus), a legume that contains the excitant amino
acid b-N-oxalylamino-L-alanine (L-BOAA).
p0060The structure of chemicals and their differential access to the
nervous system are of cardinal importance in determining the
presence and nature of the neurotoxic response. While access to
nervous tissue dictates the possibility of a direct neurotoxic
effect, neurotoxicity ultimately depends on the ability of the
substance to bind to neural tissue targets and interfere with
functional or structural integrity. Structure–activity relation-
ships are therefore of critical importance. For example,
1,2-diacetylbenzene but not 1,3-diacetylbenzene induces leg
weakness in rodents because only the former binds to and
cross-links neuroproteins, interferes with anterograde transport
of neuroﬁlaments, and causes giant proximal axonal swellings
that disrupt nerve conduction. Triethyltin targets the myelin
sheath and trimethyltin damages neurons, but tributyltin lacks
neurotoxic properties – another illustration of the critical
importance of chemical structure in determining the presence
and nature of the neurotoxic response. Even stereological
properties of molecules can dictate the presence or absence of
neurotoxic properties: L-BOAA (but not D-BOAA) is a potent
agonist of neuronal DL-a-amino-3-hydroxy-5-methyl-4-iso-
xazole propionic acid (AMPA) receptors. Only levo-naloxone
displays opioid receptor antagonistic activity, and studies
published in 2011 indicate enantioselective neurotoxicity of
chiral polychlorinated biphenyls (PCBs).
p0065The large majority of the nervous system is protected from
direct exposure to chemicals in the bloodstream and the cere-
brospinal ﬂuid (CSF) by blood–brain/nerve/CSF regulatory
interfaces. These cell-based molecular separate the microenvi-
ronmentof the brain parenchyma fromchanges in circulating ion
andmetabolite concentrations. Regulation of blood–brain/nerve
interchange is a key function of capillaries coursing through
nervous tissue. Structural specializations of capillary walls in the
form of tight junctions between adjacent endothelial cells
constitute a diffusion barrier. This allows the endothelium to
regulate the selective transport and metabolism of substances
from blood to brain and vice versa. While gases (oxygen, carbon
monoxide, nitrous oxide) cross capillary walls with ease, many
substances are excluded or their access to nervous tissue impeded
by the presence of the capillary barrier. Lipophilicity and size are
key elements in regulating the passage of macromolecules across
the blood–brain barrier. Key nutrients and macromolecules
required by the brain cross via facilitated diffusion or speciﬁc
carriers. The epithelial junctions that constitute the blood–CSF
barrier at the choroid plexus are somewhat more permeable and
allow greater passage of drugs and toxicants into the interstitial
ﬂuid that bathes brain tissue. Many metals are required for
normal CNS function and are thus transported across the blood–
brain and blood–CSF barriers. However, excess metal may
accumulate in their endothelial cells and give rise to toxic damage
of the cellular barrier. Several metals are known to accumulate
in both barriers, including substances with neurotoxic potential
such as lead, mercury, arsenic, and manganese. Lead accumulates
in the choroid plexus and alters key functions, including
transthyretin, the binding protein for thyroid hormone.
High concentrations of lead damage the blood–brain barrier
cause vascular leakage and may result in brain swelling accom-
panied by herniation, ventricular compression, and petechial
hemorrhages.
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p0070 Some regions of the brain (e.g., hypothalamus) and PNS
(spinal and autonomic ganglia) lack capillary barriers and are
thus directly exposed to chemicals circulating in the blood-
stream. Damage to the hypothalamus can have far reaching
effects on somatic metabolism, reproductive function, and
growth. The adult obesity of rats treated postnatally with
monosodium glutamate (MSG) exempliﬁes the effect and raises
important questions for human health in regard to past expo-
sure to glutamate-rich foods during postnatal development. In
the PNS, the selective loss of sensory neurons in rats treated
with doxorubicin arises because spinal ganglia lack a protective
capillary-nerve barrier.
p0075 Certain other substances (tetanus toxin) reach nerve cell
bodies directly via distal axonal entry and retrograde axonal
transport. Tetanus toxin is transported to the spinal anterior
horn cell, subsequently translocates and binds to inhibitory
presynaptic inhibitory (glycinergic) nerve terminals impinging
on the motor nerve cell, and thereby suppresses the inhibition
of motor neuron activity leading to hyperexcitation. Violent
and sustained muscle contraction (tetany) in response to
external stimulation results. Another example of peripheral
entry to the CNS is the transport and delivery of metals
(manganese, aluminum) from the nose along olfactory neurons
to the brain of laboratory animals.
p0080 The mammalian nervous system has functional design
features that predispose it to chemical perturbation. Conse-
quently, neurological dysfunction is among themost commonof
the toxic responses of humans to chemical substances. Some
neurotoxic agents perturb energy generation by interfering with
glycolysis (arsenic), while others (3-nitroprionic acid, cyanide, rote-
none) disrupt sites in the electron transport chain. Some agents
(metronidazole, misonidazole) damage brain regions such as the
brainstem nuclei that seem to have a high requirement for
glucose.
p0085Architectural design is another important determinant of
vulnerability both at the cellular and organ level. Unlike most
organs (liver, kidney, testes), the nervous system is regionally
organized; motor function, memory, vision, audition, and
olfaction require the function and interaction of different brain
regions. Whereas small lesions of the liver and kidney have
little functional impact, a chemical that damages the hippo-
campus (domoic acid), visual cortex (methylmercury), or the
peripheral vestibular and auditory system (streptomycin) may
have devastating effects on function of the organism. Moreover,
whereas tissue repair follows damage to many organs, the CNS
recovers from injury poorly. Some recovery may be afforded by
neurogenesis and/or reorganization of synaptic connections on
surviving nerve cells, but regrowth and reconnection of
damaged axons are impeded by postinjury proliferation of
astrocytes.
p0090Cellular architecture is yet another important factor in
determining vulnerability to chemical attack. Unlike most
types of mammalian cells, mature neurons and myelinating
cells in the CNS (oligodendrocytes) and PNS (Schwann cells)
possess elongated cellular processes that expose vast surface
areas of membrane to chemicals present in extracellular ﬂuid
(Figure 1). Additionally, each of these cells has a segregated
anabolic region (cell body) that is responsible for supplying the
metabolic needs of proportionately huge volumes of cytoplasm
(axons, dendrites, myelin). The unusual architecture of these
cells demands the presence of a distribution system that efﬁ-
ciently transports materials from sites of production to sites of
utilization. Within neurons, chemicals that disrupt axonal
transport (taxol, vincristine) are known to induce axonal
degeneration with consequent effects on sensory and motor
function. The special vulnerability of the longest and large-
diameter axons leads clinically to sensory dysfunction and
motor weakness in a stocking-and-glove distribution.
(a) Neuron (b)  Schwann cell
     (unfolded)
(c) Oligodendrocyte
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f0010 Figure 1 Diagram of (a) neurons, (b) Schwann cell with myelin sheath ‘unrolled,’ and (c) oligodendrocyte, to illustrate that each cell has a restricted
cell soma (S) and elongated processes that can be divided into proximal (P) and distal (D) portions. The elongated processes of these cells provide
a huge area for chemical attack.
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p0095 Neural cells are highly interconnected and dependent upon
each other’s presence and physiological activity for normal
function. Thus, chemicals that disrupt Schwann cells (diphtheria
toxin) or myelin (hexachlorophene) secondarily disturb nerve
conduction along the axonal processes of neurons with which
they are physically associated. Other agents interfere directly with
electrical transmission (pyrethroids) or the orderly conveyance of
signals via synapses (certain organophosphates) that connect nerve
cells to each other. Similarly, agents (nitrofurantoin) that cause
peripheral axons to degenerate thereby sever neuronal connec-
tions with muscle cells and cause muscle weakness.
p0100 Given the nervous system has built-in redundancy, the loss
of neurons or axons must exceed a certain threshold for clinical
effects to become apparent. That redundancy of nerve cells may
be substantially reduced with the advance of age, such that
regional loss of CNS striatal dopaminergic neurons is thought
to be a factor in dictating susceptibility to agents (carbon
disulﬁde) that can trigger parkinsonism. Similarly, age-related
spinal nerve root demyelination and distal axonal degenera-
tion of long and large-diameter axons may predispose elderly
individuals to substances that cause peripheral neuropathy
(vide infra).
s0030 Vulnerability of Neurons and Their Processes
p0105 Nerve cells are vulnerable to chemical attack at many loci,
including protein synthesis, mitochondrial, and nucleic acid
function. Somal DNA is predisposed to damage by reactive
oxygen species because of the high oxygen consumption and
metabolic activity of neurons. The cycad genotoxin MAM, an
agent that alkylates DNA with formation of O6-mG and other
adducts, interferes with neuronal development and has been
implicated in a long-latency progressive neurodegenerative
disease (O6). Adult neurons have very low levels of the speciﬁc
DNA repair enzyme, O6-methylguanine methyltransferase,
such that long-term neuronal effects might occur as a conse-
quence of unrepaired DNA damage. Mitochondrial DNA chain
growth is blocked by certain anti-HIV drugs (2’,3’-dideox-
yinosine, 2’,3’-dideoxycytidine) that cause painful axonal
neuropathy. Interference with neuronal protein synthesis
occurs with agents (ricin) that disrupt polypeptide elongation
and trigger axonal degeneration. Chemicals that alter the
mitochondrial electron transport chain (cyanide, rotenone) have
a propensity to induce basal ganglia damage. Substances (bro-
mothelin, pentachlorophenol) that uncouple electron transport
and oxidative phosphorylation elevate temperature and induce
tremor and hyperexcitability. Several neuronal enzymes are key
sites of chemical attack, including synaptic acetylcholinesterase
(organophosphates, carbamates) and neuropathy target esterase
(a subset of organophosphates), with resulting neuroexcitation
and axonal degeneration, respectively. Lead interferes with
oxidative phosphorylation by potently activating protein
kinase C.
p0110 The excitable membrane of neurons is the target of a rich
array of neurotoxins that interfere with ion channels required
for the proper functioning of neurons, axons, muscle, and glial
cells. These agents are often complex structures generated by
invertebrate species and plants presumably for purposes of
chemical defense. Sodium ion channels are common targets.
Agents that bind to the outer surface of the Naþ channel and
prevent ion inﬂux are found in dinoﬂagellates (saxitoxin),
vertebrates, including ﬁsh, octopus and salamander (tetrodo-
toxin), and cone snails (geographutoxin). Lipid-soluble anes-
thetics (lidocaine, procaine) bind to a hydrophobic site in the
channel and interfere with the gating mechanism. Activation of
Naþ channels by opening or impeding normal closure is seen
with certain plant chemicals (grayanotoxin; pyrethrin), dinoﬂa-
gellate chemicals (ciguatoxin) stored in ﬁsh, amphibian skin
toxins (batrachotoxin), scorpion a-toxins, and synthetic pesticides
(pyrethroids). Interference with Naþ channel function is usually
heralded by abnormal sensation (paresthesias) in the tongue,
around the mouth and in the extremities. While usually tran-
sient, ciguatoxin is a fat-soluble agent that may cause repeated
neurotoxic events after single exposures presumably because of
tissue sequestration and periodic release within the affected
subject. Kþ-channel toxins with selective blocking actions have
been identiﬁed in the venom of certain scorpions, bees, and snakes.
Thallium and bromine ions are transported by Kþ and Cl
channels, respectively, with signiﬁcant neurological and
psychiatric consequences for the affected subject. Calcium
channel blockers are produced by certain plants, insects, spiders,
snails, and snakes. Divalent lead ions interfere with intracellular
processes regulated by Ca2þ ions and accumulate in the same
intramitochondrial compartment as calcium. Alternative pre-
RNA splicing in the gene (Ca(V)2.2) that codes for N-type Ca2þ
channels in nociceptors modulates opioid channel inhibition
and spinal analgesia.
s0035Neurotransmitter Systems
p0115Numerous substances target mechanisms involved in neuro-
transmitter (NT) synthesis, transport, synaptic release, reup-
take, the interaction between NT and postsynaptic receptor, or
the removal of NT from the synaptic gap. Neurotoxicity occurs
when the agent reduces or increases NT release, alters NT
concentration or resident time, or acts as an agonist or anta-
gonist at a postsynaptic NT receptor.
p0120Acetylcholine synapses at neuromuscular junctions are
targets for a number of biologic and synthetic substances
(Figure 2). Neurotransmission is disrupted by agents that
interfere with choline transport (hemicholinium, choline), with
acetylcholine synthesis (triethylcholine), or synaptic vesicle
uptake (vesamicol). Other agents (b-bungarotoxin, crotoxin) target
mechanisms involved in presynaptic NT release. Botulism ari-
ses from the action of a zinc-endopeptidase (the light chain of the
botulinum toxin dipeptide) in blocking synaptic transmission by
cleaving synaptic-vesicle fusion proteins required for NT
exocytosis. Botulinum-induced blockade of normal depolar-
ization-induced NT release at the neuromuscular junction leads
to ﬂaccid muscle weakness. Conversely, a-latrotoxin in venom
of the black widow spider causes massive NT release at verte-
brate neuromuscular junctions resulting in a painful disorder
featured by dysarthria, tremor, clonic muscle contraction, and
paralysis. Numerous chemicals interfere with acetylcholines-
terase, the enzyme that terminates NT action at the neuro-
muscular junction. Certain anticholinesterases (edrophonium)
bind directly to the active center of the enzyme and act rather
brieﬂy; others (physostigmine) carbamylate the enzyme and have
longer lasting actions. The large class of organophosphates, which
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include high-potency agents used in chemical warfare and less
hazardous materials employed as agricultural pesticides,
interact with the anionic and/or esteratic sites in the active
center of acetylcholinesterase to form complexes; the stability
of the phosphorylated enzyme is further enhanced by the loss
of one of the alkyl groups, a phenomenon known as (chemical)
aging. Biological anticholinesterases include the product of
a cyanobacterium (anatoxin-a(s)) and certain snake toxins
(fasciculins).
p0125 Acetylcholine receptors provide another target for chemicals
with neurotoxic potential; most of these act as antagonists.
D-Tubocurarine is the classical nicotinic receptor antagonist,
and curare-like substances are found in elapid and hydrophid
snakes (a-neurotoxins), such as cobra (a-cobratoxin) and krait
(a-bungarotoxin), molluscs (a-conotoxin), corals (lophotoxin), and
certain plants, such as the delphinium (methyllcaconitine).
Anatoxin-a is a potent agonist at neuromuscular, autonomic, and
brain nicotinic receptors. Muscarinic receptor antagonists
include atropine, scopolamine, and the synthetic warfare agent
quinuclidinyl benzilate, which induces dryness of the mouth,
blurred vision, confusion, delirium, and coma.
p0130 Glutamate receptors, which mediate most excitatory
synaptic trafﬁc in the CNS, are another important target of
chemical substances linked to human disease. Fast synaptic
transmission is mediated by AMPA-type glutamate receptors,
a target of L-BOAA that causes pyramidal tract degeneration and
spastic paraparesis (lathyrism). Seaweed (kainic acid) and
dinoﬂagellate (domoic acid) toxins act as agonists at the kainate
subclass of glutamate receptors, the latter causing signiﬁcant
CNS neuronal excitotoxicity and CNS degeneration in humans.
Glutamate receptors that respond to N-methyl-D-aspartate
(NMDA) have numerous antagonists, including the anesthetic
agent ketamine and phencylidine (angel dust). Termination of
excitatory neurotransmission by removal of synaptic glutamate
is perturbed by dithiocarbamate pesticides. Ionotropic glutamate
receptors also play an important role in mediating neuronal
death secondary to energy deﬁcits induced by hypoxia.
p0135g-Aminobutyric acid (GABA), which is synthesized from
glutamic acid decarboxylase (GAD), is the major inhibitory NT
in the mammalian brain. GAD inhibition (2-amino-4-pentenoic
acid) induces convulsions. Numerous compounds bind to and
act as antagonists (picrotoxin) or agonists (muscimol) at GABAA
receptors, which employ chloride (Cl) channels to mediate
fast inhibitory postsynaptic potentials. Enhanced GABAergic
transmission occurs under the action of benzodiazepine and
barbiturate drugs, while organochlorine insecticides (lindane,
aldrin) exert convulsant effects mediated through picrotoxin-
binding sites.
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p0140 Glycine receptors, which mediate inhibitory neurotransmis-
sion in the brainstem and spinal cord, have a number of plant-
derived antagonists (strychnine, hydrastine) that elicit hyperreﬂexia
and tetanic muscle contraction among other signs. Tetanus toxin
from Clostridium tetanii triggers generalized muscle rigidity by
binding to glycinergic nerve terminals (and inhibiting glycine NT
release) after crossing from anterior horn cells that retrogradely
transport the agent from a peripheral wound site.
p0145 Several other NT systems and pathways are impacted by
chemicals that exhibit neurotoxicity. Dopamine mediates
communication in a number of important pathways, including
the nigrostriatal tract (a key component of basal ganglia
mechanisms for control of the quality of motor movement)
that degenerates in Parkinson disease and MPPþ-induced
toxicity. Extrapyramidal movement disorders occur as a side
effect of a number of therapeutic drugs acting on dopaminergic
pathways. Chemicals that perturb adrenergic function may
interfere with NT synthesis (a-methyltyrosine), serve as false NTs
(methyl-dopa), block vesicular uptake (reserpine), inhibit the
cleavage enzyme catechol-O-methyltransferase (pyrogallol), or
promote NT release (amphetamine). Substituted amphetamines
(MDMA) damage axons derived from the dorsal raphe
serotonergic projection system of rodents and primates.
Natural substances in plants interfere with substance P neuro-
transmission (capsaicin), cannabinoid receptors (cannabis),
purinoceptors, and adenosine receptors (caffeine). Caffeine
intoxication is characterized by anxiety, sleep disturbance, and
mood changes, while caffeine withdrawal in sensitive subjects
leads to vascular headache, drowsiness, and fatigue.
s0040 Axonal Transport
p0150 Disruption of the transport of materials along axons is another
method by which chemicals perturb neural function and induce
changes, including focal axonal pathology and axonal degener-
ation (axonopathy). Some agents interfere with the anterograde
transport of materials from sites of synthesis (cell body) to sites
of utilization (axon and terminal) (b-b’-iminodipropionitrile, 1,2-
diacetylbenzene), some with retrograde axon transport (acryl-
amide), and others with the return of materials from nerve
terminals (zinc pyridinethione). Certain plant-derived chemicals
(colchicine, vinca alkaloids) bind to tubulin, inhibit microtubule-
based function, and thereby block bidirectional axonal trans-
port. Taxol, originally isolated from the Paciﬁc yew tree, interferes
with axonal transport by promoting microtubule assembly and
stabilization. Retrograde axonal transport may also serve to ferry
foreign substances (ricin, tetanospasmin, certain metals) to targets
in neuronal somata.
s0045 Neuroglia and Myelin
p0155 Neuroglia include (1) ependymal cells lining the ventricles of the
brain and the central canal of the spinal cord; (2) cells of the PNS
(Schwann cell) and CNS (oligodendrocyte) that wrap around
axons to form compacted plasma membranes (myelin) that
provide electrical insulation to speed nerve conduction; (3) cells
(astrocytes) that interface between nerve cells and capillaries in
the CNS, regulate interstitial water content, Kþ concentration,
remove and metabolize certain NT molecules, and proliferate
following injury; and (4) microglia, which are phagocytic cells
that function as endogenous immune cells in the brain.
p0160Ependymal cells are susceptible to agents (amosconate)
present in CSF. Astrocyte foot processes investing cerebral
capillaries undergo marked swelling in water intoxication, lead
encephalopathy and in hypercapnia, and after the experimental
administration of 6-aminonicotinamide, isoniazid, misonidazole,
or ouabain. Astrocytes increase their glycogen content in
a variety of insults (methionine sulfoxamine), form intranuclear
inclusion bodies in lead intoxication, and greatly increase the
relative size of the nuclear compartment in hepatic encepha-
lopathy, which is thought to be triggered by hyperammonemia.
The food-associated mycotoxin ochratoxin A inhibits glutamate
uptake by astrocytes, which has been proposed to increase
extracellular glutamate, excitotoxicity, and neuronal loss.
p0165Myelinating cells are susceptible to substances that disrupt
the synthesis of myelin components, the best example of which
is diphtheria toxin, which has access to peripheral nerves where it
inhibits Schwann cell protein synthesis and causes primary
demyelination. Oligodendrocyte demyelination can be induced
experimentally by diphtheria toxin and by other protein
synthesis inhibitors, such as ethidium bromide and actinomycin D.
The latter induces widespread status spongiosus of white matter,
with edema ﬂuid in the periaxonal space and between myelin
membranes split open at the intraperiod line. Cuprizone (biscy-
clohexanone oxalylhydrazone) induces oligodendrocyte degenera-
tion with intramyelinic edema. Several other agents (cycloleucine,
hexachlorophene, triethyltin) trigger reversible changes in CNS and/
or PNS myelin without apparent damage or loss of the myelin-
forming cells.
s0050System Vulnerability
s0055Developing Nervous System
p0170The dominant host factor inﬂuencing response of the nervous
system to exogenous chemicals is developmental age. The
intrinsic neural factors that determine or inﬂuence response to
chemicals differ in development, at maturity, and in late life.
Thus, physiological differences between developing and adult
organisms underlie potentially signiﬁcant differences in distri-
bution, metabolism, and excretion of neurotoxic agents. As
a result, neurotoxic effects observed following developmental
exposure differ both quantitatively and qualitatively from
those seen following adult exposure. Quantitatively, the
developing nervous system is generally more sensitive to
neurotoxic agents. Studies of both humans and rodents indi-
cate that intrauterine exposure to lead or to PCBs is more
damaging to the nervous system than exposure later in life.
Neurotoxic effects may also differ qualitatively as a function of
developmental age. For example, infants of mothers treated
with the anticonvulsant drug sodium valproate may display
congenital malformations, including neural tube defects,
whereas neurotoxicity in the adult is manifest as tremor,
a confusional state and, in rare cases, parkinsonism.
p0175The inﬂuence of developmental age on the response to
neurotoxic agents largely reﬂects the susceptibility of develop-
mental processes occurring in the developing brain. Neuro-
development is a complex process that is precisely regulated in
time and space, with the basic framework of the nervous system
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laid down in a step-by-step process in which each step is
dependent upon the proper completion of the previous one. In
both humans and rodents, normal neurodevelopment begins
very early in the fetus and is not complete until puberty. Active
organogenesis, which occurs during the period from implan-
tation through mid-gestation, requires the concomitant and
coordinated ontogeny of cell proliferation, differentiation, and
migration. During late gestation and the early neonatal period,
the processes of synaptogenesis, apoptosis, and myelination
are predominant. These processes continue throughout later
stages of neurodevelopment, and together with elimination of
extraneous synapses via axon and dendrite retraction function
to reﬁne patterns of neuronal connectivity. Experimental and
clinical data suggest that errors in timing, spatial resolution, or
magnitude of any of these developmental events can have
functional consequences. For example, magnetic resonance
imaging studies of patients with schizophrenia reveal excessive
pruning of axons and dendrites in the cerebral cortex during
late adolescence, coincident with the onset of symptoms.
Importantly, substances have been identiﬁed that interfere with
each of these processes in animal models and, in some
instances, humans. The outcome of such interactions ranges
from death to gross structural abnormalities to subtle defects in
structure or function: early gestational exposure to substances
such as fumonisins can produce neural tube defects; exposure to
ionizing radiation produces altered brain morphology and
mental retardation; exposure to high concentrations of ethanol
causes mental retardation, while moderate levels of alcohol
exposure can delay motor development; intrauterine exposure
to cocaine causes excessive outgrowth of dendrites; and expo-
sure of infants and children to relatively low levels of lead is
linked to reduced scores on tests of cognitive development and
to increased aggressive tendencies.
p0180 A critical determinant of the pattern of damage induced by
neurotoxic agents is the timing of exposure relative to ongoing
ontogenetic events. For example, vitamin A and other retinoic
acid derivatives cause marked and irreversible abnormalities,
including anencephaly and spina biﬁda, when exposure occurs
during gestation days 5–10 in rats. In contrast, administration
of retinoic acid on gestational day 12 fails to perturb brain
development. There are at least four scenarios to explain how
timing of exposure inﬂuences neurotoxic outcome. First, later
stages of neurodevelopment depend on successful completion
of early stages; therefore, even relatively minor disturbances
early in neurodevelopment may cause signiﬁcantly more
damage than perturbations occurring at later stages. For
example, inhibition of cellular proliferation by agents, such as
MAM, lead, mercury, or ethanol, can subsequently impact
migration, differentiation, and ultimately neuronal connec-
tivity. Second, individual neurodevelopmental events may be
differentially vulnerable to speciﬁc substances. It has been
clearly demonstrated that speciﬁc brain regions are vulnerable
to antimitotic agents during the developmental period when
cells in these region are actively proliferating. The DNA-
damaging agent MAM disrupts regional mouse brain devel-
opment in an O6-mG-dependent manner, with little change
from normal in MAM-treated animals that overexpress the
speciﬁc DNA-repair enzyme O6-mG methyltransferase. Third,
since different brain regions develop on different time lines
during prenatal and postnatal life, a chemical may produce
impairment in different functional domains depending on the
time of exposure. Changing the time at which neonatal rats are
exposed to ethanol can trigger neuronal cell loss via apoptosis in
different brain regions, thereby giving rise to different proﬁles
of functional deﬁcits. Fourth, the expression and/or function of
target proteins can vary in the developing versus adult brain.
The alpha subunit of the glycine receptor exists in several iso-
forms that are transcriptionally regulated during development.
The adult isoforms of the alpha subunit have a higher afﬁnity
for strychnine than the neonatal isoforms; thus, the developing
nervous system is less vulnerable to strychnine than the adult.
Another important example includes NTs and enzymes that
metabolize NTs, such as acetylcholinesterase. In the adult
nervous system, these proteins function in neurotransmission;
however, during development, NTs and acetylcholinesterase
act as morphogenic factors that modulate patterns of neuronal
connectivity. Therefore, substances that target NT systems
(chlorpyrifos) may have quite different effects on the developing
fetus or child compared to the adult, and this has been
demonstrated in animal models.
p0185The potential for chemical exposure to the fetus begins
before conception in that prior parental exposure to toxicants
can have a major impact on the developing fetus. Parental
exposures threaten fetal health by either altering maternal or
paternal reproductive organs directly or via release of stored
neurotoxic agents from maternal tissues during pregnancy.
Yusho disease is a tragic example of preconception exposure to
polychlorobiphenyl compounds (PCBs) inﬂuencing fetal neuro-
development. Women in the Japanese town of Yusho who
consumed cooking oil contaminated with PCBs up to a year
prior to conception gave birth to infants exhibiting a constel-
lation of symptoms including dysmorphism, skin lesions,
hepatic dysfunction, and cognitive abnormalities. PCBs stored
in maternal tissues were mobilized during pregnancy. Simi-
larly, lead can be mobilized from storage depots in bone
during pregnancy. Once in the maternal blood supply,
chemicals may diffuse across the placenta and enter the fetal
circulation. Some agents (organoarsenicals) accumulate in the
placenta, which shields the offspring from exposure. However,
the placenta does not block small molecular weight
compounds (carbon monoxide), lipophilic compounds (PCBs,
ethanol, methylmercury), or compounds using active transport
mechanisms (lead). Once in the fetal circulation, the devel-
oping brain is protected by the same brain barrier mechanisms
that protect the adult brain. Contrary to a long-standing belief,
functional brain barrier mechanisms are in place after neural
tube closure. The vulnerability of the developing brain may be
enhanced, however, by inward transport mechanisms for
nutrients such as amino acids, glucose, and trace metals, which
are more active than in the adult brain and thus may facilitate
the entry of neurotoxins such as mercury, lead, and manga-
nese. The lower concentration of proteins in fetal and neonatal
plasma may allow their binding capacity for drugs and toxi-
cants (heavy metals) to be exceeded more easily than in the
adult. In addition, the presence of transport mechanisms that
are unique to the developing brain may similarly increase the
vulnerability of the developing brain. Prior to keratinization of
the human fetal epidermis, beginning at 20 weeks of gestation,
exogenous chemicals may also diffuse from the amniotic ﬂuid
into the developing fetus. After birth, exposure to potential
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toxicants may occur via breastfeeding and consumption of
other contaminated foodstuffs, oral contact via hand-to-
mouth activity, dermal contact, or inhalation. Compared with
adults, children in all postnatal developmental stages have
higher rates of respiration and energy consumption per kilo-
gram of body weight, which increases their exposure rates.
In addition, skin is highly permeable during the newborn
period and several epidemics of developmental neurotoxicity
have been described involving percutaneous absorption of
chemicals. These include hypothyroidism from iodine in
povidone iodine (Betadine) scrub solutions and myelin disorders
consequent to bathing infants in hexachlorophene. The expres-
sion of Phase I and Phase II metabolic enzymes is also
developmentally regulated, resulting in altered abilities of
developing organisms to detoxify and excrete chemicals rela-
tive to adults. This difference may confer increased resistance
when a substance must be metabolized to an active metabo-
lite. But, more frequently, the metabolic differences manifest
as a decreased capacity of children to excrete toxins as
compared to adults, and thus they are more vulnerable to
certain neurotoxic agents. The lack of functional paroxonase,
the enzyme that detoxiﬁes many organophosphates, contributes
to the increased vulnerability of the developing nervous
system to the neurotoxic effects of these agents.
p0190 Many chemicals are recognized teratogens in animals;
a signiﬁcantly smaller subset of these is known or suspected to
cause toxic effects in the developing human nervous system.
Some of the more signiﬁcant human developmental neuro-
toxicants include ethanol, which causes a constellation of
effects ranging from fetal alcohol syndrome to alcohol-related
neurodevelopmental disorder; maternal tobacco use (fetal
tobacco syndrome); excess vitamins A and D; metals, particularly
inorganic and organic mercury, lead, arsenic, magnesium, and
cadmium; anticonvulsants, such as phenytoin, valproate, pheno-
barbital, carbamazepine, and primidone; drugs of abuse, including
cocaine, cannabis, andmescaline; persistent aromatic hydrocarbons,
especially PCBs; and both organochlorine and organophosphate
pesticides.
p0195 Detecting effects in the human population is difﬁcult
because they may be subtle (small shifts in IQ scores, slight
changes in behavior) or because neurotoxicity does not become
manifest until a signiﬁcant period of time after the develop-
mental exposure. Delayed neurotoxicity may arise via two
different mechanisms. One of these involves a developmental
insult in which anatomical and/or functional effects may be
masked or attenuated initially because of compensatory
mechanisms or plasticity. However, these developmental
perturbations predispose the individual to neural deﬁcits
following subsequent insults, such as chemical exposure,
disease, or aging because of decreased reserve capacity. This
phenomenon has been demonstrated in animal models for
organochlorine pesticides, and in both animal models and
humans following developmental exposures to methyl mercury.
The second mechanism involves the occurrence of a toxic insult
early in neurodevelopment, but with manifestation of the
pathological change much later in neurodevelopment when
function of the affected cells is normally activated. An agent
that causes this type of delayed neurotoxicity experimentally is
the food additivemonosodium glutamate (MSG). Developmental
exposure to MSG causes excessive apoptosis of neurons via
activation of NMDA glutamate receptors in the developing
hypothalamus. However, the fetal loss of these hypothalamic
neurons becomes evident (as hypogonadism and infertility)
only in adolescence when the neuroendocrine function of these
neurons is normally activated.
p0200The identiﬁcation of the food additive MSG as a potential
developmental neurotoxicant triggered studies of other
substances that modulate excitatory and/or inhibitory
neurotransmission in the developing brain. The culmination
of this work is the recognition that neuroactive compounds
that either block NMDA glutamate receptors or promote
inhibitory neurotransmission at GABAA receptors can also
trigger neuronal apoptosis in the immature rodent brain.
Ethanol, which has both NMDA antagonist and GABA mimetic
properties, causes enhanced neuronal apoptosis relative to
compounds with only one of these activities. The period of
peak vulnerability for this toxic effect coincides with the
developmental period of rapid synaptogenesis, also known as
the brain growth spurt, which occurs in the early postnatal
period in mice and rats, and from the third trimester to several
years after birth in humans. These studies have generated
signiﬁcant concern in the clinical setting because a number of
anesthetics used in pregnant women and infants function by
blocking NMDA receptors (ketamine) or promoting GABA
neurotransmission (midazolam, diazepam, propofol). These
anesthetic drugs have been shown to cause widespread
developmental neurodegeneration via apoptosis and persis-
tent cognitive deﬁcits in rodents exposed to clinically relevant
levels, and similar effects have been demonstrated for ket-
amine in nonhuman primates. Recent epidemiological studies
support a link between brief anesthesia exposure during early
infancy and poor neurodevelopmental outcome; however,
interpretation is confounded by the potential impact of the
surgical procedure, concurrent illness, or coexisting pathology.
This case study is an illustration of some of the issues asso-
ciated with conﬁrming developmental neurotoxicity in
humans, even for compounds with known mechanisms of
action.
p0205Additional emerging issues in developmental neuro-
toxicology that merit mention include endocrine disruption
as a mechanism of developmental neurotoxicity and gene–
environment interactions as determinants of risk and/or
severity of neurodevelopmental disorders. With respect to
the former, sex steroids, thyroid hormones, and neuropep-
tides are known to modulate key neurodevelopmental
processes including neuronal differentiation, migration,
survival and apoptosis, neuronal connectivity, and synaptic
plasticity. Alteration of hormonal status during brain devel-
opment can cause functional deﬁcits in adolescence and
adulthood, as illustrated by cognitive dysfunction associated
with fetal hypothyroidism. While a number of chemicals with
known endocrine disrupting activity have been shown to
interfere with neurodevelopment (PCBs, bisphenol A), it
remains to be established whether the developmental
neurotoxicity of these compounds is mediated by endocrine
disruption and whether endocrine disruption alters neuro-
development in humans.
p0210The second emerging issue in developmental neuro-
toxicology reﬂects a growing consensus that environmental
factors, potentially including environmental pollutants,
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drugs, or dietary factors, interact with genes of susceptibility
to determine risk and/or variable expression of complex
neurodevelopmental disorders, including autism spectrum
disorder (ASD), attention-deﬁcit disorder, and schizophrenia.
This paradigm shift is driven in part by evidence that the
prevalence of neurodevelopmental disorders is increasing. For
examples, decades ago, ASD was considered rare, occurring in
approximately 1 in 2500 individuals. The Centers for Disease
Control and Prevention reported that in 2002, 1 in 150 eight-
year-old children in the United States had ASD. More recent
data indicate that the current prevalence of ASD is between 1
in 90 and 1 in 64. While this increased prevalence can be
attributed in part to the broadening of diagnostic criteria and
greater awareness of ASD in recent years, recent studies
conﬁrm that these factors alone do not fully explain the
observed increase in the prevalence of ASD. This implies that
environmental factors are contributing to the rapid increase
in ASD prevalence. Additionally, a number of studies have
now documented genetic mutations linked to neuro-
developmental disorders that are expressed in both a non-
affected parent and an affected child, further supporting the
concept that environmental factors determine risk and/or
severity. Direct ‘proof-of-concept’ evidence in support of
the hypothesis that environmental factors inﬂuence risk of
neurodevelopmental disorders comes from clinical and
epidemiological studies linking ASD with perinatal exposure
to viruses such as rubella and cytomegalovirus, chronic
inﬂammation, and gestational exposure to potent teratogens
including thalidomide, valproic acid, hydantoin, and ethanol.
Exposure during critical phases of development to antithyroid
agents (certain plant ﬂavonoids, mercury, perchlorate, thiocyanate)
has been proposed as an avenue of research in relation to
autism. Sources of antithyroid substance thiocyanate (the
major metabolite of cyanide) include tobacco smoke and
numerous cyanogenic plants used for food.
p0215 Gene–environment interactions have been proposed (e.g.,
organophosphorus pesticides and genetic mutations in the gene
encoding paraoxonase-1, the enzyme that detoxiﬁes these
pesticides that have been linked to ASD) but as yet, there is
no deﬁnitive evidence of a speciﬁc gene–environment inter-
action that confers susceptibility to a neurodevelopmental
disorder. However, examples of environmentally triggered
diseases associated with mutations in RYR, the gene that
encodes the ryanodine receptor, provide support for this
hypothesis. Humans who are heterozygous for these muta-
tions are fully viable and asymptomatic, but they respond
adversely to halogenated hydrocarbon anesthetics with a fulmi-
nant malignant hyperthermic episode. Interestingly, it has
been reported that the nondioxin-like PCB 95 is signiﬁcantly
more potent and efﬁcacious in disrupting cation regulation
by ryanodine receptors expressing mutations associated with
malignant hyperthermia than by wild-type ryanodine
receptors.
s0060 Adult Nervous System
p0220 Chemicals generally perturb neurological function of the adult
by interfering differentially with the structure and function of
speciﬁc neural pathways, circuits, and systems. Vulnerable
circuits within the brain include those that modulate and effect
efferent output. Most commonly affected, however, are the
peripheral neurons in pathways that relay information to and
from the brain.
p0225The special senses of vision, audition, balance, gustation,
and olfaction depend on neural pathways that originate in
peripheral receptors and terminate in the brainstem or cere-
bral cortex. Afferent pathways for taste, smell, hearing, and
balance employ sensory neurons in ganglia that lack a blood–
nerve barrier. However, chemicals that perturb the special
senses seem most commonly to interfere with the structure or
function of the peripheral sensory receptors. Olfaction and
gustation are subserved by cilia-bearing sensory neurons that
are continuously generated from stem cells, a process of
cellular replacement that is disrupted by antiproliferative
drugs such as vincristine and doxorubicin. For vision, the
function of retinal cells is perturbed by a large number
of substances, some of which produce reversible change
(cardiac glycosides and trimethadone), while others (amino-
phenoxyalkanes) elicit morphological damage. For retinal
ganglion cells, the nerve ﬁbers that form the optic pathway are
sites of vulnerability to toxic attack. Substances that impair
energy metabolism (thallium, cyanide) tend to damage prox-
imal regions of axons projecting into the optic nerve from the
papillomacular bundle, while distal axonal degeneration,
with damage to the optic tracts, is seen with drugs such as
clioquinol and ethambutol. Vestibular and auditory function
may be affected concurrently by agents that target receptor
cells in the inner ear of rodents (2-butenenitrile, 2-penteneni-
trile) and humans (streptomycin). Other potentially ototoxic
substances include cisplatin, furosemide, and imipramine. Noise
may exacerbate the neurotoxic effects of some ototoxic agents.
Disturbance of human oculomotor function may take the
form of nystagmus (carbon monoxide) or opsoclonus (chlor-
decone), two types of abnormal eye movement. Certain
neurotoxic substances produce lesions of vestibular and
cochlear nuclei in rodents (6-chloro-6-deoxyglucose) and
primates (1-amino-6-chloropropane).
p0230Sensorimotor function is altered by a number of chemicals
that act at different sites in the neuraxis. Most affect the axons
or somata of lower motor neurons in the anterior horn of the
spinal cord or primary sensory neurons in dorsal root ganglia.
Some substances target the nerve cell body of sensory neurons
that detect touch and vibration (methylmercury), position sense
(pyridoxine), or pain (capsaicin), or of neurons that regulate
cardiac muscle (doxorubicin) or voluntary muscle function
(domoic acid, b-N-methylamino-L-alanine). Others target motor
nerve terminals (botulinum toxin, a-latrotoxin) or the enzyme
that targets acetylcholine NT (anticholinesterases), both of which
produced acute alterations of neurotransmission associated
with reduced or enhanced synaptic transmission. Temporary
disruption of electrical impulse conduction is another neuro-
toxic effect. Agents (pyrethroids, ciguatoxin, tetrodotoxin) that
perturb electrical activity in the excitable membrane (axo-
lemma) of the nerve cell produce rapidly reversible sensory
abnormalities (paresthesias) in the distribution of trigeminal
and elongate peripheral nerves. Those substances (hexachloro-
phene, ethidium bromide) that attack the myelin sheath or mye-
linating cell precipitate focal demyelination and remyelination,
with consequent disruption and restoration of nerve conduc-
tion and associated sensory motor phenomena over a period of
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several weeks. Focal demyelination and remyelination may
also result from exposure to chemicals that block neuroﬁla-
ment transport and cause focal axonal swellings to develop
proximally (1,2-diacetylbenzene, 3,4-dimethyl-2,5-hexanedione)
or distally (2,5-hexanedione, carbon disulﬁde, acrylamide).
Chemicals that produce distal (acrylamide), but not proximal
(b-b’-iminodipropionitrile), giant axonal neuroﬁlamentous
swellings trigger retrograde distal axonal degeneration (distal
axonopathy). Long and large-diameter myelinated axons in the
PNS and CNS are vulnerable to distal axonopathy caused by
a number of compounds (organophosphates, isoniazid, thalido-
mide), the resulting clinical picture being one of symmetrical
sensory loss and muscle weakness in the distal extremities
(stocking-and-glove polyneuropathy). Shorter and thinner
nerve ﬁbers, including postganglionic nerves of the autonomic
nervous system, may become involved in distal axonopathies.
This common type of neurodegeneration usually occurs after
repeated exposure, evolves during and shortly after the period
of intoxication, and then reverses as regenerating axons rees-
tablish functional contact with denervated sensory terminals
and muscle. Signiﬁcant atrophy may result from prolonged
skeletal muscle denervation, and recovery of sensory-motor
function may be slow, progressive, and incomplete. When
central motor pathways are heavily impacted by distal axono-
pathy (leptophos, clioquinol), those affected may display
permanent residual spasticity.
p0235 The motor pathway from brain to muscle is modulated by
two other CNS structures that are vulnerable to substances
with neurotoxic potential, namely the basal ganglia and
cerebellum. Damage to the cerebellum may result in loss of
coordination of limb and eye movement and in an ataxic gait
(methylmercury, 3-acetylpyridine). Sida carpinifolia and Ipomea
carnea are rich in swainsonine, a toxin that inhibits the enzyme
alpha mannosidase and induces a cerebellar syndrome. The
cerebellum and basal ganglia are both sensitive to hypoxia
and related states induced by agents that impair energy
metabolism (cyanide) and promote glutamate-mediated
excitotoxicity. Other energy-disrupting agents elicit neuronal
damage in the putamen (3-nitropropionic acid, methanol), pal-
lidum (carbon monoxide), substantia nigra (MPTP, paraquat),
or other parts of the basal ganglia (manganese). These types of
neurotoxicity may ﬁnd clinical expression as parkinsonism,
tremor, dystonia, and other clinical signs of extrapyramidal
dysfunction. Movement disorders of various types may result
from the side effects of several therapeutic agents (amphet-
amines, anticonvulsants, anticholinergics, neuroleptics, dopamine
agonists, lithium, tricyclic antidepressants). Atypical parkin-
sonism has been linked to ingestion of fruit of the Annona-
ceae family (corossol, soursop), which contain isoquinolinic
alkaloids and acetogenins. A large component of aspartate,
together with glutamate, is found in water-soluble compo-
nent of the Yellow Star thistle (Centaurea solstitialis), which
together with Russian knapweed (Acroptilon repens), induces
a degenerative extrapyramidal disorder in horses known as
equine nigropallidal encephalomalacia.
p0240 Autonomic regulation of the pupil, lacrimal and salivary
glands, airway, heart, gut, bladder, genitalia, and blood vessels
involves sympathetic, parasympathetic, and enteric neurons.
Unlike their somatic counterparts in the spinal cord, efferent
neurons of the autonomic nervous system are housed in
peripheral ganglia with permeant blood vessels. Autonomic
function is disrupted by agents that target synapses that utilize
acetylcholine since this is the principal NT for all preganglionic
autonomic ﬁbers, all postganglionic parasympathetic ﬁbers,
and some postganglionic sympathetic ﬁbers. Drugs that
selectively block nicotinic receptors (curare) curtail ganglionic
output, while muscarinic agents (atropine) block transmission
to effector cells. Anticholinesterase agents (fasciculins, organo-
phosphates) stimulate sympathetic and parasympathetic
activity, sometimes with the dramatic clinical consequences of
a cholinergic crisis (nerve agents). Direct contact of anticho-
linesterase nerve agents (sarin, O-ethyl S-2-diisopropylaminoethyl
methylphosphonothioate, or VX) with the eye, nasal passages, and
bronchi leads to pupillary constriction (miosis), blurred
vision, rhinorrhea, bronchoconstriction, and increased secre-
tions. Systemic exposure results in creased salivation, brady-
cardia, enhanced lacrimation, urination, and defecation.
Attendant muscle fasciculation, weakness, and seizures arise
from peripheral somatic and CNS actions of anticholinesterase
nerve agents.
p0245The autonomic nervous system and endocrine function are
regulated by the hypothalamus and associated limbic struc-
tures of the brain. Hypothalamic functions, including the
regulation of temperature, heart rate, blood pressure, blood
osmolarity, circadian control, and water and food intake, may
be impacted by a range of chemicals. Parts of the hypothal-
amus lack a blood–brain barrier: Infant mice treated with
excitotoxic agents (glutamate, aspartate, cysteic acid) display
extensive damage of the arcuate nucleus and develop
a syndrome of obesity, skeletal stunting, reproductive failure,
and gonadal hypoplasia. The hypothalamus receives major
input from the hippocampus, which functions in the storage
of declarative memory, uses cellular circuitry that involves
glutamatergic synapses vulnerable to excitotoxins (domoic
acid) and certain other agents (trimethyltin, trimethyl lead,
soman), the latter possibly as a result of seizure-associated
hypoxia.
See also: 00003; 00005; 00006; 00014; 00021; 00022; 00035;
00040; 00045; 00048; 00051; 00079; 00099; 00106; 00115;
00116; 00117; 00131; 00132; 00141; 00142; 00158; 00181;
00191; 00194; 00240; 00256; 00288; 00313; 00325; 00363;
00379; 00386; 00397; 00436; 00445; 00475; 00482; 00512;
00513; 00519; 00521; 00595; 00608; 00609; 00635; 00648;
00650; 00654; 00655; 00668; 00669; 00684; 00691; 00692;
00695; 00696; 00697; 00703; 00706; 00715; 00716; 00717;
00740; 00744; 00745; 00747; 00748; 00749; 00750, 00751;
00756; 00777; 00788; 00790; 00791; 00796; 00810; 00815;
00816; 00817; 00818; 00819; 00822; 00849; 00868; 00869;
00873; 00875; 00877; 00879; 00880; 00881; 00893; 00899;
00919; 00925; 00936; 00938; 00941; 00945; 00955; 00957;
00984; 00998; 01063; 01068.
Further Reading
Brust, J.C.M., 1993. Neurological Aspects of Substance Abuse. Butterworth-Heine-
mann, Boston, MA.
Creeley, C.E., Olney, J.W., 2010. The young: Neuroapoptosis induced by anesthetics
and what to do about it. Anesth. Analg. 110, 442–448.
Neurotoxicity 11
TXE3 00169
Feldman, R.G., 1998. Occupational and Environmental Neurotoxicology. Lippincott-
Raven, Philadelphia, PA.
Grandjean, P., Landrigan, P.J., 2006. Developmental neurotoxicity of industrial
chemicals. Lancet 368, 2167–2178.
Herken, H., Hucho, F., 1994. Selective Neurotoxicity. Springer-Verlag, Berlin,
Germany.
Panzica, G.C., Bo, E., Martini, M.A., Miceli, D., Mura, E., Viglietti-Panzica, C., Gotti, S.,
2011. Neuropeptides and enzymes are targets for the action of endocrine dis-
rupting chemicals in the vertebrate brain. J. Toxicol. Environ. Health B Crit. Rev.
14, 449–472.
Parent, A.S., Naveau, E., Gerard, A., Westbrook, G.L., 2011. Early developmental
actions of endocrine disruptors on the hypothalamus, hippocampus and cerebral
cortex. J. Toxicol. Environ. Health B Crit. Rev. 14, 328–345.
Pessah, I.N., Lein, P.J., 2008. Evidence for environmental susceptibility in Autism:
what we need to know about gene x environment interactions. In: Zimmerman, A.
(Ed.), Autism: Current Theories and Evidence. Humana Press, Totowa, NJ,
pp. 409–428.
Rice, D., Barone, S., 2000. Critical periods of vulnerability for the developing nervous
system: evidence from humans and animal models. Environ. Health Perspect. 108,
511–533.
Román, G.C., 2007. Autism: transient in utero hypothyroxemia related to maternal;
ﬂavanoid ingestion during pregnancy and to other antithyroid agents. J. Neuro. Sci.
262, 15–26.
Spencer, P.S., Schaumburg, H.H., 1980. Experimental and Clinical Neurotoxicology.
William and Wilkins, Baltimore, MD.
Spencer, P.S., Schaumburg, H.H., 2000. Experimental and Clinical Neurotoxicology.
Oxford, New York.
Tu, A.T., 1984–1992. Handbook of Natural Toxins, vols. 2–7. Marcel Dekker, New York.
Vinken, P.J., Bruyn, G.W., 1994–5. Handbook of Clinical Neurology: Intoxications of
the Nervous System, vols. 64–65. Elsevier, New York.
Yasui, M., Strong, M.J., Ota, K., Verity, M.A., 1997. Mineral and Metal Neurotoxicity.
CRC Press, Boca Raton, FL.
Zawia, N.H., 2004. Molecular Neurotoxicology: Environmental Agents and Transcription-
Transduction Coupling. CRC Press, Boca Raton, FL.
12 Neurotoxicity
TXE3 00169
